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Abstract: Antimicrobials are an extremely valuable resource across the spectrum of modern 
medicine. Their development has been associated with dramatic reductions in communicable 
disease mortality and has facilitated technological advances in cancer therapy, transplantation, 
and surgery. However, this resource is threatened by the dwindling supply of new antimicrobi-
als and the global increase in antimicrobial resistance. There is an urgent need for antimicro-
bial stewardship (AMS) to protect our remaining antimicrobials for future generations. AMS 
emphasizes sensible, appropriate antimicrobial management for the benefit of the individual 
and society as a whole. Within the English National Health Service (NHS), a series of recent 
policy initiatives have focused on all aspects of AMS, including best practice guidelines for 
antimicrobial prescribing, enhanced surveillance mechanisms for monitoring antimicrobial use 
across primary and secondary care, and new prescribing competencies for doctors in training. 
Here we provide a concise summary to clarify the current position and importance of AMS within 
the NHS and review the evidence base for AMS recommendations. The evidence supports the 
impact of AMS strategies on modifying prescribing practice in hospitals, with beneficial effects 
on both antimicrobial resistance and the incidence of Clostridium difficile, and no evidence of 
increased sepsis-related mortality. There is also a promising role for novel diagnostic technolo-
gies in AMS, both in enhancing microbiological diagnosis and improving the specificity of 
sepsis diagnosis. More work is needed to establish an evidence base for interventions to improve 
public and patient education regarding the role of antibiotics in common clinical syndromes, 
such as respiratory tract infection. Future priorities include establishing novel approaches to 
antimicrobial management (eg, duration of therapy, combination regimens) to protect against 
resistance and working with the pharmaceutical industry to promote the development of new 
antimicrobials.
Keywords: antimicrobial resistance, antibiotics, National Health Service, methicillin-resistant 
Staphylococcus aureus, Clostridium difficile, prescribing
Introduction
Alongside vaccines and public health measures to control transmission of communi-
cable diseases, antibiotics have helped to dramatically reduce mortality from infec-
tious disease during the 20th century.1 This success generated a sense of complacency 
among some figures in public health and academia in the 1960s and 1970s.2 As Sir 
Frank Burnett, in accepting his Nobel prize for medicine in 1962, put it: “One can 
think of the middle of the twentieth century as the end of one of the most important 
social revolutions in history, the virtual elimination of the infectious diseases as a 
significant factor in social life.”3 However, the enduring global challenge of patho-
gens such as influenza, tuberculosis, and malaria, as well as the emergence of human 
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immunodeficiency virus, means that infectious disease 
remains an important problem.4
The real value of antibiotics goes beyond simply prevent-
ing death and illness due to infection, in that antibiotics also 
permit the serious iatrogenic assault on the immune system 
occurring in cancer treatment or organ transplantation and 
have helped to keep surgical complication rates down.5 There-
fore, antibiotics are an extremely valuable resource across 
the spectrum of modern medicine.6 However, the supply of 
new antibiotics has slowed dramatically, with only one or 
two agents targeting Gram-negative pathogens likely to be 
brought to market in the next decade.7
Antimicrobial stewardship
There is an urgent need to protect our current antimicro-
bial drugs for future generations.8 Antimicrobials can be 
 conserved by judicious use to limit the development of 
antimicrobial resistance (AMR);9 this is the core component 
of antimicrobial stewardship (AMS).10 Additional benefits of 
AMS include preventing the selection of opportunistic patho-
gens such as Clostridium difficile,11 limiting exposure to 
toxicities associated with misuse of antimicrobials,10 and 
direct economic savings through reduced complication rates 
and antimicrobial consumption.12 AMS emphasizes sensible, 
appropriate antimicrobial management for the benefit of the 
individual and society as a whole.5,13
Antimicrobial resistance
There is a clear role for AMS in controlling AMR. 
 Microorganisms invariably develop resistance in response to 
the evolutionary pressure exerted upon them by exposure to 
antimicrobials.14 This fact was recognized by Sir Alexander 
Fleming in his initial studies of the antibiotic properties of 
the Penicillium fungus. He cautioned, in his Nobel prize 
acceptance speech in 1945, that misuse of penicillin could 
contribute to development of AMR which could in turn com-
promise its usefulness. The history of treatment for  Neisseria 
gonorrhoeae illustrates this point; the gonococcus has 
sequentially developed resistance against most antimicrobial 
agents to which it has been exposed, including sulfonamides, 
penicillin, quinolones, and now some cephalosporins,13 
 leaving multidrug-resistant N. gonorrhoeae isolates for which 
there are very few therapeutic options.15
This fearsome prospect of untreatable infection also applies 
to several other organisms. The Infectious  Diseases Society of 
America has termed the main culprits the “ESKAPE patho-
gens”16 (Table 1), but the biggest global concern is AMR in 
Gram-negative bacteria.  Enterobacteriaceae such as Escherichia 
coli or Klebsiella species that are resistant to all but one or two 
antimicrobials have evolved as a consequence of extremely 
high levels of antibiotic exposure in several parts of the world, 
including Asia and the Middle East.17 Infections with these 
multidrug-resistant organisms are associated with approximately 
two-fold higher mortality rates and considerably prolonged 
hospital admissions.17 In 2009, the European Centre for Disease 
Prevention and Control estimated that AMR costs the European 
Union €1.5  billion in health care expenses and lost productiv-
ity per year.18 Nosocomial transmission has caused outbreaks 
in health care facilities, and international travel has facilitated 
global dissemination.17 A history of hospitalization overseas 
has become a personal risk factor for acquisition of multidrug-
resistant organisms.19 In a recent survey, approximately one third 
of healthy travelers to Asia became asymptomatically colonized 
with multidrug-resistant  Enterobacteriaceae despite low levels 
of health care contact.20 Such asymptomatic carriage is also sig-
nificantly higher in people in the UK from certain demographic 
groups with links to high incidence regions.21
However, there is cause for optimism that this threat can 
be contained. Some European countries, such as Sweden, 
have pioneered stewardship programs that have success-
fully reduced antibiotic use and kept AMR rates low.9 An 
AMS program in Scotland has had an important impact 
Table 1 eSKAPe pathogens
Gram-positive Gram-negative
Enterococcus faecium Klebsiella species
Acinetobacter baumannii
Staphylococcus aureus Pseudomonas aeruginosa
Enterobacter species and Escherichia coli
Note: Data from Boucher et al.16
Table 2 UK 5 year antimicrobial resistance strategy 2013–2018
Strategic aims Improve the knowledge and understanding of AMR
Conserve and steward the effectiveness of existing 
treatments
Stimulate the development of new antibiotics, 
diagnostics, and novel therapies
Seven key areas  
for action
Improving infection prevention and control practices
Optimizing prescribing practice
Improving professional education, training, and 
public engagement
Developing new drugs, treatments, and diagnostics
Better access to and use of surveillance data
Better identification and prioritization of AMR 
research needs
Strengthened international collaboration
Note: Adapted from Department of Health, Department for environment, Food and 
Rural Affairs. UK Five Year Antimicrobial Resistance Strategy 2013–2018. Available 
from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/ 
244058/20130902_UK_5_year_AMR_strategy.pdf.23
Abbreviation: AMR, antimicrobial resistance.
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on  antimicrobial consumption and C. difficile rates.22 AMS 
programs also appear to have had a significant impact in the 
English hospital setting.7 The incidences of both methicillin-
resistant Staphylococcus aureus and C. difficile peaked in the 
mid 2000s, and it is believed that a combination of restrictive 
antimicrobial policies and better infection prevention and 
control practices (eg, source isolation and handwashing) were 
responsible for the decreasing incidence of both infections,5 
although it is not clear which of these interventions had the 
dominant role. At the global level, the problem of AMR in 
England is comparatively minor at present. However, with a 
relatively narrow focus on methicillin-resistant S. aureus and 
C. difficile, the growing problem of bacteremia due to other 
multidrug-resistant organisms has been largely ignored.7
AMR is an emergent threat to health care delivery within 
the National Health Service (NHS) in England.5 A multiplicity 
of government documents, recommendations, and position 
statements on AMS to address AMR in the English NHS have 
been produced over the last few years. Here we provide a timely 
summary of these publications to help clarify the current posi-
tion and importance of AMS to the NHS in England. We outline 
the evidence base underpinning the AMS recommendations, 
and conclude with a discussion of future priorities.
Antimicrobial stewardship 
initiatives in the NHS
Concerns regarding the rise of AMR and the priority of AMS 
were recently highlighted by the Chief Medical Officer, 
Dame Sally Davies, in her annual report of 2011, published 
in March 2013.5 This report received a lot of attention and 
provided much needed focus for AMS leadership.7 The report 
addressed four broad areas of AMS:13
•	 Concerns about global AMR
•	 The need to raise awareness and education about AMR 
among the public and within the NHS
•	 The need for better surveillance systems for AMR
•	 The need to improve diagnostics.
In parallel with the Chief Medical Officer’s report, a UK 
pan-governmental strategy and action plan for AMR has 
been recently published (see Table 2).23 However, awareness 
of AMR in the UK is not a recent development; a series of 
reports and policy initiatives has addressed AMR in the NHS 
over the last two decades, as summarized in Table 3. “The Path 
of Least Resistance” (1998)24 first outlined the AMS impera-
tives for the NHS. Introducing several stewardship themes 
that are recognizable in subsequent reports, it highlighted the 
need for antimicrobial prescribing to be evidence-based and 
supported by national formularies, and emphasized the need 
for antimicrobial prescribing to take a more prominent place 
in medical education, to utilize the expertise of infection spe-
cialists, and for resources to be directed towards research into 
developing strategies to combat AMR.24 Following this, the 
UK Department of Health produced several reports on AMR/
AMS, starting with the first UK “Antimicrobial Resistance 
Strategy and Action Plan” in 2000.25 The Health and Social 
Care Act 200826 provided a framework for the Care Quality 
Commission to objectively measure the quality of health care 
provision, and specifically included AMS outcomes. Criterion 
9 states: “Procedures should be in place to ensure prudent 
prescribing and antimicrobial stewardship.”
There should be an ongoing program of audit, revision, 
and update. In health care, this is usually monitored by 
the antimicrobial management team or local prescribing 
advisors. To provide practical guidance for NHS providers, 
the Antimicrobial Stewardship in Primary Care collabora-
tion was formed in 2009. This multiagency collaboration 
produced a multifaceted AMS intervention for primary 
care that was launched in 2012. The Treat Antibiotics 
 Responsibly,  Guidance and Education Toolkit (TARGET)27 
contains evidence-based resources for clinician and patient 
 education, as well as specific antimicrobial guidance and 
self-assessment and audit tools. Also in 2012, the  Department 
of Health’s Advisory Committee on Antimicrobial Resistance 
Table 3 Key antimicrobial stewardship initiatives in the National 
Health Service
Report Year Agency
The Path of Least Resistance 1998 Medical Advisory 
Committee
UK Antimicrobial Resistance  
Strategy and Action Plan
2000 Department of Health
winning ways: working  
together to reduce Healthcare  
Associated Infection in england
2003 Department of Health
The Health Act 2006 Department of Health
Saving Lives: Reducing Infection,  
Delivering Clean and Safe Care
2007 Department of Health
Health and Social Care Act: a Code  
of Practice on the Prevention and  
Control of Infections
2008 Department of Health
TARGeT toolkit 2009 Antimicrobial Stewardship 
in Primary Care
Start Smart then Focus 2012 Advisory Committee on 
Antimicrobial Resistance 
and Healthcare 
Associated Infection
english Surveillance Programme  
for Antimicrobial Utilization  
and Resistance
2013 Public Health england
Abbreviation: TARGeT, Treat Antibiotics Responsibly, Guidance and education 
Toolkit.
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and Healthcare Associated Infection produced the “Start 
Smart and Focus” guidance18 to provide a framework for 
best antimicrobial prescribing practice. Included within Start 
Smart and Focus is the Acute Hospital’s Assessment Tool,28 
an evidence-based checklist for AMS assessment and audit. 
Overall, these publications aim to standardize the practice 
of AMS across the NHS in England in both primary and 
secondary care settings.
Antimicrobial prescribing  
in the NHS
It is challenging to accurately assess current prescribing pat-
terns across the NHS in England. Whilst the Health and Social 
Care Information Centre monitors antimicrobial dispensing 
data in primary care, there is no routine public reporting of 
antimicrobial use in hospitals.29 For this, we must rely on 
intermittent antibiotic point prevalence surveys, such as that 
done in 2011 by the Health Protection Agency.5 Within the 
NHS, most antimicrobial prescribing (up to 80%) happens 
in primary care. However, despite awareness of the problem 
of resistance and the raft of AMS reports discussed above 
(Table 3), there was a 16% increase in antimicrobial prescrip-
tions in primary care between 2002 and 2012.29 The “NHS 
Atlas of Variation in Health Care” also describes a three-fold 
variation in quinolone prescriptions and an 18-fold variation 
in cephalosporin prescriptions across primary care trusts 
in England in 2010.18 Such regional variation also applies 
to inpatient antimicrobial prescriptions (which vary in the 
range of 29%–39.9% for inpatients) and seems not to be 
driven solely by demographic factors or regional variation in 
burden of disease.5
Surveillance
More detailed understanding of patterns of antimicrobial use 
will be of central importance when directing and assessing the 
impact of AMS programs in England. As a result, Public Health 
England has developed the English Surveillance Programme 
for Antimicrobial Utilization and Resistance to monitor anti-
microbial prescribing and resistance in primary and secondary 
care.29 The English Surveillance Programme for Antimicrobial 
Utilization and Resistance also has the remit to develop qual-
ity measures and methods to monitor unintended outcomes of 
AMS and educational/behavioral interventions.29
Education and training
The desire for more training in antimicrobial prescribing 
has been identified in surveys of both doctors in training30 
and  medical students.31 Trainee doctors generally view 
comprehensive antimicrobial prescribing guidelines 
positively,30 although surveys continue to show that when 
prescriptions are noncompliant with guidelines, the antibiotic 
choice tends to be broader spectrum but not more appropriate 
to the organism,32 suggesting that efforts to improve adher-
ence with guidelines are warranted. Growing recognition 
that the principles of antimicrobial prescribing and steward-
ship are central to the practice of medicine in the UK has 
led to the development of specific antimicrobial prescribing 
competencies within a 2012 report entitled “A single com-
petency framework for all prescribers”,33 developed by the 
National Prescribing Centre on behalf of the National  Institute 
for Clinical Excellence, which has been endorsed by the 
 General Medical Council and the Academy of Medical Royal 
Colleges. To complement the National Prescribing Centre 
competency framework, five specific antimicrobial prescrib-
ing and stewardship competencies have been recently released 
by the Advisory Committee on Antimicrobial Resistance and 
Healthcare Associated Infection.34 These cover infection pre-
vention and control, AMR, antimicrobial prescribing, AMS, 
and monitoring and learning. The need for better education 
and training does not just apply to health care professionals. 
As consumers of antimicrobials, it is vital to engage patients 
and members of the public in AMS campaigns.
Public engagement
Public misconceptions about the role of antibiotics in viral 
infections35 indicate a need for better education, and surveys 
have shown that among various reasons cited by practi-
tioners for inappropriate antibiotic prescriptions, patient 
expectation was highly influential.36,37 Annual European 
Antibiotic Awareness Days (EAAD) aim to improve public 
understanding about the appropriate role for antibiotics in 
common clinical scenarios.38 However, in a recent survey 
performed in conjunction with EAAD, approximately 35% 
of those surveyed in the UK were unaware that antibiotics 
have no effect in viral infection.38 Some interventions such 
as the English 2008 poster-based EAAD educational pro-
gram had a negligible impact on antimicrobial knowledge 
or consumption.39 However, other simple practical measures 
such as an interactive booklet on respiratory infections in 
children supplied in primary care have been shown to sig-
nificantly reduce antibiotic prescriptions without reducing 
parental satisfaction;40 this booklet is included in the TAR-
GET toolkit.27 Whilst the need for better patient education 
about the role of antibiotics is widely acknowledged,5,12,13 
there is also a need for more evidence-based guidance 
about how best to achieve this. However, the main focus 
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
11
6 
on
 2
4-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Importance of antimicrobial stewardship to the english NHS
of AMS is on reducing antimicrobial prescribing by health 
care professionals, and we summarize evidence for such 
interventions below.
Evidence base for AMS 
interventions
Primary care
A variety of heterogeneous AMS interventions in the primary 
care setting have been evaluated.41 The main objective is to 
reduce antimicrobial prescribing for  various infections, par-
ticularly respiratory tract infection (which is most commonly 
viral41) as well as uncomplicated urinary tract infection and 
otitis media, or reducing the prescription of specific agents. 
A previous Cochrane review42 indicated that multifaceted 
interventions tailored to precise target populations were 
most likely to have significant effects on prescribing. Recent 
randomized controlled trials have evaluated multifaceted 
interventions43,44 with positive effects on reducing antibiotic 
prescribing rates. However, few studies have been sufficiently 
powered, designed, or tested interventions with sufficient 
effect sizes to show an impact on AMR.42
Secondary care
The effectiveness of AMS interventions on inpatient 
prescribing has been the subject of a recently updated 
Cochrane systematic review and meta-analysis.45 Inter-
vention studies have evaluated the effect of persuasive 
interventions (including circulation of educational mate-
rial, educational meetings, and audit and feedback) and 
restrictive measures (including reporting selective antimi-
crobial sensitivities, formulary restrictions, and mandatory 
prior infection specialist approval for certain drugs) in 
reducing inappropriate antimicrobial prescriptions. The 
majority of interventions (in 84% of studies) focused 
on the antimicrobial prescribed, whereas the remainder 
addressed whether or not antibiotics should be prescribed 
at all. Both restrictive and persuasive interventions were 
effective in randomized controlled trials (median effect 
size 40.5% versus 24.7%, respectively). In a meta-analysis 
of 52 studies, restrictive interventions had significantly 
greater impact on prescribing outcomes at one month 
(32%, 95% confidence interval [CI] 2–61, P=0.03) and 
on microbial outcomes at 6 months (53%, 95% CI 31–75, 
P=0.001) but there were no significant differences at 12 or 
24 months. Several beneficial outcomes were associated 
with reduced antimicrobial prescribing (regardless of how 
it was achieved), such as reduced C. difficile, methicillin-
resistant S. aureus, and extended spectrum beta-lactamase 
Enterobacteriaceae rates. In addition, whilst there was no 
clinical evidence of increased mortality in nine studies 
aimed at reducing antibiotic exposure, four studies focus-
ing on optimizing prescribing for community-acquired 
pneumonia showed a significant improvement in mortal-
ity (risk ratio 0.89, 95% CI 0.82–0.97). Overall, these 
data indicate that AMS interventions are effective and 
evidence-based, and support restrictive interventions when 
short-term improvements are required.
Diagnostics
Delay in administering effective antibiotics results in step-
wise increases in mortality resulting from bacterial sepsis.46 
From the perspective of AMS this presents a paradox, given 
that as AMR becomes more prevalent the need for clinicians 
to use empirical broad spectrum antibiotics in patients with 
severe sepsis will become greater, driving selection of resis-
tant microorganisms and exacerbating the problem. Strategies 
to improve the diagnosis of serious infection with multidrug-
resistant organisms are a particular focus of AMS programs 
to guide the appropriate use of broad-spectrum therapy and 
avoid unnecessary antibiotic exposure. The role for novel 
diagnostic technologies lies in rapid identification of caus-
ative organisms (which permits targeted, narrow-spectrum 
therapy), as well as in improving the specificity of sepsis 
diagnosis (given that many patients with a systemic inflam-
matory response do not have serious bacterial infection and 
therefore do not require antibiotic therapy). Developments 
in this field are the subject of a recent review.12
Biomarkers
The use of biomarkers has been shown to aid the clinical 
diagnosis of infection and to reduce unnecessary antibiotic 
prescriptions.5 For example, the inclusion of the biomarker 
procalcitonin in an antibiotic management algorithm has been 
shown in randomized controlled trials47 and in pragmatic 
clinical trials48 to safely reduce the frequency and duration 
of antibiotic therapy for suspected lower respiratory tract 
infection, and to enhance de-escalation of broad-spectrum 
antibiotics in cancer patients49 and critical care patients50 with 
infection. In a recent meta-analysis, procalcitonin combined 
with careful clinical assessment had a sensitivity of 0.77 and 
specificity of 0.79 for the diagnosis of sepsis compared with 
systemic inflammatory response of noninfective etiology,51 
and preliminary studies suggest it can be used safely in NHS 
medical admission settings.52 The use of C-reactive protein as a 
biomarker in primary care AMS initiatives has shown efficacy 
in reducing antimicrobial prescriptions (reviewed in Moore41). 
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Algorithms incorporating newer biomarkers, alone or in 
combination, are also under investigation,12 but more data are 
required before their definitive role can be established.
Rapid microbiological diagnosis
Current microbiological diagnosis is inefficient, with a 
minimum lag of 48 hours between the isolate reaching the 
laboratory and accurate organism identification. Molecular 
techniques have the potential to greatly speed up microbio-
logical diagnosis and could also be used to detect genomic 
resistance, thus reducing exposure to unnecessary broad-
spectrum antibiotics. With sufficient sensitivity, they could 
also play a part in determining whether antibiotics need to 
be prescribed or not. These techniques broadly involve either 
proteomic or genomic methods.
Matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) detects the proteomic 
signature of an array of pathogens, and can yield diagnostic 
information in a matter of minutes.53 The utility of MALDI-
TOF in the AMS setting has been demonstrated in proof 
of concept studies.54 However, technical issues currently 
preclude its more widespread application, such as difficul-
ties in distinguishing certain bacterial species and problems 
identifying polymicrobial infections.12
Additional molecular techniques, such as nucleic acid 
amplification or nucleic acid hybridization, are in clinical 
use for pathogen detection (eg, identifying N. gonorrhoeae, 
 Chlamydia trachomatis, C. difficile, and several other 
pathogens). Rapid nucleic acid amplification kits can also 
identify resistance mutations, such as the mecA gene in 
methicillin-resistant S. aureus.55 Next-generation whole 
genome sequencing has greater potential applicability to 
AMS, in view of its ability to simultaneously identify sev-
eral pathogens as well as potential resistance mutations, as 
well as its ability to provide early indications of outbreaks 
through analysis of the relatedness of pathogen genomes in 
different patients.56 However, much work remains before 
these technologies are available for cost-effective routine 
diagnostic applications.56
Conclusion and  
outstanding challenges
In this review, we have outlined the current status of AMS in 
the English NHS, including national policies and guidance, 
the evidence base for intervention strategies, and issues of 
education, training, and improved diagnostic technologies. 
However, there are a number of outstanding challenges in 
the field of stewardship and AMR.
One important strategy to combat the potential threat of 
untreatable infection is to accelerate the development of novel 
antimicrobials, although this is unlikely to happen without 
extensive commercial and/or political incentives, such as tax 
breaks, government funding, financial rewards for specific 
outcomes, simplified regulatory requirements, or extended 
patents.5 One such example is the 2012 US Generating Anti-
biotic Incentives Now (GAIN) Act. Clearly, AMS will remain 
of critical importance to protect any future antimicrobials 
developed through such effort.
Another priority for future work is to define the opti-
mal duration of antimicrobial prescribing, for example, 
whether antibiotic conservation through short-duration 
regimens is safe and effective in limiting the develop-
ment of resistance.5 Additional strategies that have been 
suggested include the use of combinations of antibiotics 
from different classes (as is used in antiretroviral therapy 
for human immunodeficiency virus) or the cycling of first-
choice antibiotics in empirical prescribing guidelines to 
avoid prolonged exposure.5
Here we have summarized the current status and impor-
tance of AMS to the NHS in England, and outlined the evidence 
base for current and potential AMS programs. The ultimate 
success of AMS may well determine to a large degree the future 
scope, utility, and effectiveness of the English NHS.
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